Abstract: The disclosure provides a polypeptide with a mutation having cellobiohydrolase activity and improved thermal stability.

Abstract: Methods for producing intein-modified proteases are provided. Expression cassettes and vectors for using to genetically engineer hosts are described. Hosts genetically engineered to express one or more intein-modified proteases using expression cassettes and vectors of the invention are also provided. Methods to produce a protease and regulate its activity are described.

Abstract: Recombinant collagenases with a stable specific activity and enzyme agents for cell and tissue dissociation such a recombinant are provided. The recombinant collagenase is derived from Grimontia hollisae-derived collagenase is characterized by having, from the N terminus to the C terminus, a collagenase catalytic domain, a linker region sequence, and a prepeptidase C terminal domain, which Grimontia hollisae-derived recombinant collagenase does not comprise at least the prepeptidase C terminal domain. The obtained recombinant collagenase has a high and stable specific activity.

Abstract: The present application relates to a method of reducing the content of dimers in Factor VII polypeptide composition by heat treatment.

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.

Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.

Abstract: The present system provides novel methods and compositions for selecting a particular strand of RNA and/or producing a cDNA library that results in an unbiased representation of RNA in a sample.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of hemipteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of hemipteran pests, and the plant cells and plants obtained thereby.

Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.

Abstract: The present invention relates to the use of an E3 ligase RNF185 inhibitor for treating cystic fibrosis and chronic obstructive pulmonary disease.

Abstract: A nucleic acid molecule comprises a nucleotide sequence: as shown in SEQ ID No. 1, which is the complement of SEQ ID No. 1, which is degenerate with SEQ ID No. 1, or which has at least 85% sequence identity with SEQ ID No. 1, or which is a part of such a sequence. The nucleic acid molecule encodes or is a complementary to a nucleic acid molecule encoding one or more polypeptides, or comprises or is complementary to a nucleic acid molecule comprising one or more genetic elements, having functional activity in the synthesis of a polyketide-based or macrolactam molecule. The nucleic acid molecule may be used to prepare a modified BE-14106 biosynthetic gene cluster for the preparation of a modified BE-14106 molecule.

Abstract: The present invention relates to a recombinant nucleic acid molecule, a recombinant microorganism, to a method for producing alanine and to the use of the recombinant nucleic acid molecule or the recombinant microorganism for the fermentative production of alanine.

Abstract: The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of these DNA molecules.

Abstract: The present invention relates to the field of chromosome engineering. More specifically, the present invention provides methods and compositions useful for inducibly linearizing circular DNA molecules in vivo in yeast. In one embodiment, a comprises a nucleic acid encoding a selectable marker, wherein the nucleic acid encoding a selectable marker comprises an intron comprising an endonuclease recognition site flanked by telomere seed sequences.

Abstract: Provided are vector constructs and methods for expressing a transgene in plant cells and/or plant tissues using gene regulatory elements, including the promoters, 5?-UTRs, and/or 3?-UTRs, isolated from Zea mays.

Abstract: Provided are vector constructs and methods for expressing a transgene in plant cells and/or plant tissues using gene regulatory elements, including the promoters, 5?-UTRs, introns, and/or 3?-UTRs, isolated from Zea mays.

Abstract: Expression vectors and expression cassettes containing a tissue specific 5? transcription regulatory element, optionally linked to a translation regulatory element, optionally linked to an intron transcription regulatory element, operably linked to a heterologous polynucleotide encoding a protein or RNA of interest are described. The 5? transcription regulatory elements control expression in root tissue cells, phloem tissue cells, or fruit and/or abscission zone tissue cells. These sequences are obtained from citrus plants. Methods of use of these expression vectors and expression cassettes are described, as well as genetically altered plants and parts thereof that contain these expression vectors and/or cassettes.

Abstract: The present invention provides a polynucleotide having a function of regulating a content of a plant metabolite, a polypeptide having a function of regulating a content of a plant metabolite, a vector containing the polynucleotide or a part of the polynucleotide, and a transformed plant produced by using the vector. Examples of such polynucleotides or polypeptides include polynucleotides or polypeptides with homology with quinolinate synthase or those which are predicted to be transcription factors. A method for producing the transformed plant is additionally included.

Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.

Abstract: This disclosure provides transgenic plants, including crop plants and methods for their production. The transgenic plants comprise recombinant DNA constructs for the expression of polypeptides encoded by the DNA constructs. The polypeptides are capable of conferring improved traits to the transgenic plants when expressed under the control of a tissue-enhanced promoter. This disclosure also pertains to transgenic plants and their progeny plants, wherein the transgenic or progeny plants comprise the recombinant DNA constructs and are selected for having enhanced nitrogen use efficiency and/or nitrogen uptake. Seed of the transgenic plants that can be grown into a plant that comprise the disclosed recombinant DNA constructs and exhibits having enhanced nitrogen use efficiency, and which may be selected for this trait, are also envisioned.

Abstract: The present invention relates to methods and compositions for identifying, selecting and/or producing a maize plant or maize plant part having increased yield under non-drought conditions, increased yield stability under drought conditions, and/or increased drought tolerance. A maize plant or maize plant part, including any progeny and/or seeds derived from a maize plant or germplasm identified, selected and/or produced by any of the methods of the present invention is also provided.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of hemipteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of hemipteran pests, and the plant cells and plants obtained thereby.

Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3?-untranslated region element (3?-UTR) element comprising a nucleic acid sequence which is derived from the 3?-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3?-UTR element comprising a nucleic acid sequence which is derived from the 3?-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3?-UTR element.

Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.

Abstract: Methods for modulating T-type calcium channel activity without directly targeting the T-type calcium channels are provided that include modulating kelch-like protein 1 (KLHL1) levels in a subject by providing a small hairpin RNA (shRNA) that targets a KLHL1 gene, and then administering the shRNA to the subject in an amount sufficient to modulate KLHL1 gene expression. The KLHL1 level directly effects current activity in T-type calcium channels and therefore modulation of KLHL 1 gene expression indirectly modulates current activity in T-type calcium channels. The methods may be implemented with, for example, an shRNA molecule suitable for modulating a KLHL1 level in the subject which may be provided as a plasmid encoding the shRNA molecule or an adeno-associated virus vector encoding the shRNA molecule. Methods of identifying compounds that modulate current activity in T-type calcium channels by determining an effect of the compound on KLHL1 gene expression are also provided.

Abstract: An object of the present invention is to provide a method for efficiently recovering solid selenium or gaseous selenium from wastewater/waste using a microorganism. The present invention provides a method for recovering selenium, comprising reducing a water-soluble selenium compound so as to produce elemental selenium or gaseous selenium by allowing a sample containing a water-soluble selenium compound to come into contact at a temperature which is more than 35° C. and is 40° C. or less at pH 7.0 to 9.4 with a microorganism capable of producing elemental selenium or gaseous selenium through reduction of a water-soluble selenium compound.

Abstract: The invention relates to a method for the simultaneous production of a fermented, solid product and ethanol comprising the following steps: 1) providing a mixture of milled or flaked or otherwise disintegrated biomass, comprising oligosaccharides and/or polysaccharides and live yeast in a dry matter ratio of from 2:1 to 100:1, and water; 2) fermenting the mixture resulting from step (1) under conditions where the water content in the initial mixture does not exceed 65% by weight, for 1-36 hours at a temperature of about 25-60° C. under anaerobic conditions; 3) incubating the fermented mixture resulting from step (2) for 0.5-240 minutes at a temperature of about 70-150° C.

Abstract: The present invention provides a microorganism capable of fermenting arabinose to a desired product such as ethanol. In some embodiments, the organism is also capable of fermenting xylose. In some embodiments, the organism is capable of fermenting arabinose and xylose, and expresses one or more cellulases.

Abstract: There is described a method for producing 3-hydroxypropanal, the method comprising: culturing an Acetobacter lovaniensis bacterium in a growth medium containing phosphate at a level which is more than 1 g/liter and nitrate at a level which is more than 0.1 g/liter, wherein culturing of the bacterium produces the 3-hydroxypropanal. The 3-hydroxypropanal can be separated from the growth medium or, when the microorganism has converted some or all of the 3-hydroxypropanal to 3-hydroxypropionic acid and/or a 3-hydroxypropionate ester, it may be separated as 3-hydroxypropionic acid or a 3-hydroxypropionate ester. The separated product can be converted into other chemicals such as an ester of 3-hydroxypropionic acid, 3-hydroxypropionic acid, 3 -hydroxypropionate salts (including ammonium, sodium and calcium 3-hydroxypropionate), acrylic acid, acrylates, acrylamide, acrylonitrile, acrolein and 1,3 propanediol.

Abstract: It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

Abstract: The present invention provides various combinations of genetic modifications to a transformed host cell that provide increase conversion of carbon to a chemical product. The present invention also provides methods of fermentation and methods of making various chemical products.

Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.

Abstract: A method for producing an objective substance is provided. An objective substance is produced by culturing a microorganism which has been modified so that the activity of a dicarboxylic acid exporter protein is reduced in a medium, and collecting the objective substance from the medium.

Abstract: Methods for detecting abdominal aortic aneurysm (AAA) or predisposition to AAA in a apoE subject, methods for monitoring the efficacy of treatment of AAA in a subject, and methods for evaluating the severity of AAA or risk of AAA in a subject involve measuring the amount of tetrahydrobiopterin (H4B) present in the test sample and comparing it to the amount of H4B present in a standard or previous test sample. A decreased amount of H4B present in the test sample compared to the standard is indicative of AAA or predisposition to AAA. Treatment can be administered to the subject prior to a second time point, and an increased amount of H4B present in the second test sample compared to the first test sample is indicative of effective treatment of AAA. Candidates can be identified for further testing or monitoring for AAA, and/or for treatment for AAA.

Abstract: Apparatus for automated venting and/or sampling of a specimen container having a closure sealing the interior of the specimen container from the environment is disclosed. The apparatus includes a rack holding the specimen container; a venting and/or sampling device having a needle, a chamber in fluid communication with the needle and a port in fluid communication with the chamber; a robotic transfer mechanism moveable relative to the rack; a sample removal apparatus attached to the robotic transfer mechanism having gripping features for gripping the venting device.

Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.

Abstract: A novel method for isolating DNA from juices and ciders is described. This method is low cost and yield large quantities of highly purified DNA even though one uses a small quantity of juice or cider. A method for determining if a juice or cider is safe to consume and/or the quality of the juice or cider are also described. For these methods, one can perform qPCR on the DNA which can be obtained using the disclosed method or any other prior art method, and comparing the amount of DNA from microorganisms is present in the juice and/or cider to determine the safety and/or quality of the juice and/or cider. These methods work even if the liquid was pasteurized.

Abstract: Provided herein is technology relating to isolating nucleic acids. In particular, the technology relates to methods and kits for extracting nucleic acids from problematic samples such as stool.

Abstract: A parallel processing system for processing samples is described. In one embodiment, the parallel processing system includes an instrument interface parallel controller to control a tray motor driving system, a close-loop heater control and detection system, a magnetic particle transfer system, a reagent release system, a reagent pre-mix pumping system and a wash buffer pumping system.

Abstract: Described herein are systems for analysis of biopolymers and complexes containing biopolymers based on optical measurement of ion flux through pores. Also described are methods of using such devices for analysis of biopolymers and complexes containing biopolymers, including methods of determining the nucleotide sequences of polynucleotides.

Abstract: Embodiments of the invention include a method for fabricating a semiconductor device, the resulting structure, and a method for using the resulting structure. A substrate is provided. A hard mask layer is patterned over at least a portion of the substrate. Regions of the substrate not protected by the hard mask are doped to form a source region and a drain region. The hard mask layer is removed. A dielectric layer is deposited on the substrate. An insulative layer is deposited on the dielectric layer. A nano-channel is created by etching a portion of the insulative layer which passes over the source region and the drain region.

Abstract: Compositions, methods and kits are disclosed for high-sensitivity single molecule digital counting by the stochastic labeling of a collection of identical molecules by attachment of a diverse set of labels. Each copy of a molecule randomly chooses from a non-depleting reservoir of diverse labels. Detection may be by a variety of methods including hybridization based or sequencing. Molecules that would otherwise be identical in information content can be labeled to create a separately detectable product that is unique or approximately unique in a collection. This stochastic transformation relaxes the problem of counting molecules from one of locating and identifying identical molecules to a series of binary digital questions detecting whether preprogrammed labels are present. The methods may be used, for example, to estimate the number of separate molecules of a given type or types within a sample.

Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.

Abstract: The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient ischemic attacks (TIA).

Abstract: The invention provides methods and reagents for diagnosing breast cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.

Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.

Abstract: Disclosed are nucleic acid sequences, including microRNA sequences and cDNA sequences, as well as vectors, DNA libraries, microarrays, and recombinant cells comprising the nucleic acid sequences described herein. Methods of determining the B cell stage from which a B cell malignancy is derived. Methods of identifying B cell malignancies are also provided. Methods of diagnosing B cell malignancies are provided. Such methods comprise, in certain embodiments, detecting one or more microRNAs or cDNAs as disclosed herein.